Cargando…

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer

PURPOSE: More accurate prediction of patient outcome based on molecular subtype is required to identify patients who will benefit from specific treatments. METHODS: We selected novel 16 candidate prognostic genes, including 10 proliferation-related genes (p-genes) and 6 immune response-related genes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Jinil, Choi, Yoon-La, Kim, Haein, Choi, Jun Young, Lee, Se Kyung, Lee, Jeong Eon, Choi, Joon-Seok, Park, Sarah, Choi, Jong-Sun, Kim, Young Deug, Nam, Seok Jin, Nam, Byung-Ho, Kwon, Mi Jeong, Shin, Young Kee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487710/ https://www.ncbi.nlm.nih.gov/pubmed/28409241 http://dx.doi.org/10.1007/s10549-017-4234-4

Ejemplares similares

UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer
por: Kim, Yu-Jin, et al.
Publicado: (2020)

BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2018)

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
por: Kim, Sangmin, et al.
Publicado: (2012)

A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2− early breast cancer
por: Gong, Gyungyub, et al.
Publicado: (2017)

The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer
por: Park, Woong Ki, et al.
Publicado: (2023)

Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2− Early Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2021)

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2019)

Diagnostic Value of FDG PET/CT in Surveillance after Curative Resection of Breast Cancer
por: Lee, Hwanhee, et al.
Publicado: (2023)

Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay
por: Lee, Jun-Hee, et al.
Publicado: (2022)

Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients
por: Jeong, Hae Min, et al.
Publicado: (2017)

Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study
por: Kwak, Youngji, et al.
Publicado: (2023)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Suppression of Platelet-Derived Growth Factor Receptor-Alpha Overcomes Resistance to Trastuzumab through STAT3-Dependent IL-6 Reduction in HER2-Positive Breast Cancer Cells
por: Kim, Sangmin, et al.
Publicado: (2023)

Involvement of a Gr2a-Expressing Drosophila Pharyngeal Gustatory Receptor Neuron in Regulation of Aversion to High-Salt Foods
por: Kim, Haein, et al.
Publicado: (2017)

Berberine Suppresses TNF-α-induced MMP-9 and Cell Invasion through Inhibition of AP-1 Activity in MDA-MB-231 Human Breast Cancer Cells
por: Kim, Sangmin, et al.
Publicado: (2008)

Characterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database: Matched-Pair Analysis of Patients With Female Breast Cancer
por: Choi, Min-Young, et al.
Publicado: (2016)

Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
por: Choi, Hee Jun, et al.
Publicado: (2023)

Oncologic Outcomes of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Patients with Tumor-Nipple Distance Less than 2.0 cm
por: Alsharif, Emad, et al.
Publicado: (2019)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway
por: Lee, Jieun, et al.
Publicado: (2019)

Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction
por: Jeon, Myeongjin, et al.
Publicado: (2016)

Development of a Nomogram to Predict N2 or N3 Stage in T1–2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy
por: Kim, Isaac, et al.
Publicado: (2017)

Predictive biological factors for late survival in patients with HER2-positive breast cancer
por: Kang, Young-Joon, et al.
Publicado: (2023)

Erratum: Development of a Nomogram to Predict N2 or N3 Stage in T1-2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy
por: Kim, Isaac, et al.
Publicado: (2018)

Metformin induces caspase-dependent and caspase-independent apoptosis in human bladder cancer T24 cells
por: Jang, Ji Hoon, et al.
Publicado: (2020)

A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer
por: Lee, Sae Byul, et al.
Publicado: (2018)

Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing
por: Lee, Chan Gyu, et al.
Publicado: (2021)

Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses
por: Jeon, Insu, et al.
Publicado: (2020)

Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2017)

Is Sentinel Lymph Node Biopsy for Breast Cancer with Cytology-Proven Axillary Metastasis Safe? A Prospective Single-Arm Study
por: Choi, Hee Jun, et al.
Publicado: (2021)

Septal Reduction Using Transvenous Intramyocardial Cerclage Radiofrequency Ablation: Preclinical Feasibility
por: Shin, Eun-Seok, et al.
Publicado: (2020)

A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
por: Reix, Nathalie, et al.
Publicado: (2016)

Polyostotic Fibrous Dysplasia Mimicking Multiple Bone Metastases in a Patient with Ductal Carcinoma In Situ
por: Lee, Jun Ho, et al.
Publicado: (2014)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

Surgical impact on anxiety of patients with breast cancer: 12-month follow-up prospective longitudinal study
por: Kim, Jiyoung, et al.
Publicado: (2020)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

Long-Term Outcome of Internal Mammary Lymph Node Detected by Lymphoscintigraphy in Early Breast Cancer
por: Koo, Min Young, et al.
Publicado: (2012)

Body Mass Index with Tumor (18)F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer
por: Hyun, Seung Hyup, et al.
Publicado: (2016)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qput195m7rslnhikjl822gejfo